[go: up one dir, main page]

PE20091617A1 - Tiazolil-dihidro-indazoles - Google Patents

Tiazolil-dihidro-indazoles

Info

Publication number
PE20091617A1
PE20091617A1 PE2009000361A PE2009000361A PE20091617A1 PE 20091617 A1 PE20091617 A1 PE 20091617A1 PE 2009000361 A PE2009000361 A PE 2009000361A PE 2009000361 A PE2009000361 A PE 2009000361A PE 20091617 A1 PE20091617 A1 PE 20091617A1
Authority
PE
Peru
Prior art keywords
dihydro
benzothiazol
pyridin
acetamide
phenyl
Prior art date
Application number
PE2009000361A
Other languages
English (en)
Inventor
Darryl Mcconneli
Maria Impagnatiello
Dirk Heinz Kesler
Oliver Kraemer
Siegfried Schneider
Der Veen Lars Van
Ulrike Weyer-Czernilofsky
Tobias Wunberg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39591172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091617(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20091617A1 publication Critical patent/PE20091617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TIAZOLIL-DIHIDRO-INDAZOLES DE FORMULA (1) DONDE R1 ES -NHRc, -NHC(O)Rc, -NHC(O)ORc, ENTRE OTROS, DONDE Rc ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C10), ENTRE OTROS; R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C8), ARILO(C6-C10), ENTRE OTROS; R3 ES HETEROARILO DE 6, 8, 9 Y 10 MIEMBROS OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: N-[1-(4-BROMO-FENIL)-3-(6-METIL-PIRIDIN-3-IL)-4,5-DIHIDRO-1H-PIRAZOLO[4,3-g]BENZOTIAZOL-7-IL]-ACETAMIDA, N-{3-(6-METIL-PIRIDIN-3-IL)-1-[4-(4,4,5,5-TETRAMETIL-1,3,2-DIOXABOROLAN-2-IL)-FENIL]-4,5-DIHIDRO-1H-PIRAZOLO[4,3-g]BENZOTIAZOL-7-IL}-ACETAMIDA, N-[1-(4-BROMO-FENIL)-3-(6-ETILAMINO-PIRIDIN-3-IL)-4,5-DIHIDRO-1H-PIRAZOLO[4,3-g]BENZOTIAZOL-7-IL]-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS DE CICLO CELULAR ESPECIFICAS SIENDO UTILES EN EL TRATAMIENTO DE CANCER
PE2009000361A 2008-03-13 2009-03-11 Tiazolil-dihidro-indazoles PE20091617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08152721 2008-03-13

Publications (1)

Publication Number Publication Date
PE20091617A1 true PE20091617A1 (es) 2009-11-12

Family

ID=39591172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000361A PE20091617A1 (es) 2008-03-13 2009-03-11 Tiazolil-dihidro-indazoles

Country Status (21)

Country Link
US (2) US20110118208A1 (es)
EP (1) EP2280982A1 (es)
JP (1) JP2011513471A (es)
KR (1) KR20100135743A (es)
CN (1) CN102015728A (es)
AR (1) AR070877A1 (es)
AU (1) AU2009224659A1 (es)
BR (1) BRPI0908583A2 (es)
CA (1) CA2717488A1 (es)
CL (1) CL2009000599A1 (es)
CO (1) CO6290768A2 (es)
EA (1) EA201001427A1 (es)
EC (1) ECSP10010532A (es)
IL (1) IL207776A0 (es)
MA (1) MA32158B1 (es)
MX (1) MX2010009837A (es)
PE (1) PE20091617A1 (es)
TW (1) TW200942548A (es)
UY (1) UY31700A (es)
WO (1) WO2009112565A1 (es)
ZA (1) ZA201006023B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
RS56432B1 (sr) 2009-11-05 2018-01-31 Rhizen Pharmaceuticals S A Novi benzopiran modulatori kinaze
US8466162B2 (en) 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
EP2546249A1 (en) 2011-07-15 2013-01-16 Boehringer Ingelheim International Gmbh 5-Alkynyl-pyridines
TW201245176A (en) 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
AU2013285081B2 (en) 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
EP2343303A1 (de) * 2004-10-07 2011-07-13 Boehringer Ingelheim International GmbH PI3-Kinase Inhibitoren
DE102004048877A1 (de) * 2004-10-07 2006-04-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg PI3-Kinasen
AU2007233729A1 (en) * 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyldihydroindazole derivatives as protein kinase inhibitors
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
CA2646536A1 (en) 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyl dihydro-indazoles
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole

Also Published As

Publication number Publication date
KR20100135743A (ko) 2010-12-27
CO6290768A2 (es) 2011-06-20
MX2010009837A (es) 2010-09-28
JP2011513471A (ja) 2011-04-28
ECSP10010532A (es) 2010-11-30
CA2717488A1 (en) 2009-09-17
CN102015728A (zh) 2011-04-13
IL207776A0 (en) 2010-12-30
BRPI0908583A2 (pt) 2019-09-24
EP2280982A1 (en) 2011-02-09
US20120108567A1 (en) 2012-05-03
TW200942548A (en) 2009-10-16
AR070877A1 (es) 2010-05-12
US20110118208A1 (en) 2011-05-19
WO2009112565A1 (en) 2009-09-17
UY31700A (es) 2009-11-10
EA201001427A1 (ru) 2011-04-29
CL2009000599A1 (es) 2011-01-07
ZA201006023B (en) 2011-10-26
US8304556B2 (en) 2012-11-06
AU2009224659A1 (en) 2009-09-17
MA32158B1 (fr) 2011-03-01

Similar Documents

Publication Publication Date Title
PE20091617A1 (es) Tiazolil-dihidro-indazoles
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20141375A1 (es) Activadores de glucoquinasa
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20141075A1 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20090773A1 (es) Derivados de morfolina pirimidina
ATE522526T1 (de) 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen
PE20141681A1 (es) Inhibidores de btk
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
NO20091626L (no) MGLUR5-modulatorer
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
EA201200653A1 (ru) Гетариламинохинолины
PE20080828A1 (es) Compuestos y composiciones como inhibidores de la quinasa proteica
CL2010001608A1 (es) Compuestos derivados de 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-4,5-dihidro-2h-isoquinolin-1-ona y 2-(3-(5-oxo-4,5-dihidro-pirazin-2-il)-fenil)-3,4-dihidro-2h-isoquinolin-1-ona, inhibidores de quinasa; composicion farmaceutica; utiles en el tratamiento de estados patologicos inflamatorios y/o inmunes.
EA201070422A1 (ru) Производные оксадиазола

Legal Events

Date Code Title Description
FD Application declared void or lapsed